PDGF-CC, human recombinant | 7183

The platelet-derived growth factor (PDGF) family of heparin-binding growth factors consists of five known members, denoted PDGF-AA, PDGF-BB, PDGF-AB, PDGF-CC and PDGF-DD. The mature and active form of these proteins, an anti-parallel disulfide-linked dimer of two 12-14 kDa polypeptide chains, is obtained through proteolytic processing of biologically inactive precursor proteins, which contain an N-terminal CUB domain and a PDGF/VEGF homologous domain. The PDGFs interact with two related protein tyrosine kinase receptors, PDGFR- and PDGFR-, and are potent mitogens for a variety of cell types, including smooth muscle cells, connective tissue cells, bone and cartilage cells, and certain tumor cells. They play an important role in a number of biological processes, including hyperplasia, chemotaxis, embryonic neuron development, and respiratory tubules epithelial cell development. Mature PDGFs are stored in platelet -granules and are released upon platelet activation. PDGF-AA, -AB, -BB and –CC signal primarily through the PDGF-R receptor, whereas PDGF-DD interacts almost exclusively with the PDGF-R receptor. Recombinant human PDGF-CC is a 25kDa protein consisting of two identical disulfide-linked 112 amino-acid polypeptide chains.

7183 | PDGF-CC human recombinant DataSheet

Biomolecule/Target: PDGFC

Synonyms: Platelet-Derived Growth Factor-CC

Alternates names: soluble IL-4 receptor alpha, CD124

Taglines: Potent mitogen for a variety of cell types

NCBI Gene ID #: 3566

NCBI Gene Symbol: IL4RA

Gene Source: Human

Accession #: P24394

Recombinant: Yes

Source: HEK293 cells

Purity by SDS-PAGEs: 98%

Assay: SDS-PAGE

Purity: N/A

Assay #2: HPLC

Endotoxin Level: < 0.1 ng/g of protein (<1EU/g).

Activity (Specifications/test method): Determined by its ability to inhibit the IL-4-dependent proliferation of human TF-1 cells. The expected ED50 is 5.0 ng/ml (in the presence of 0.5 ng/ml of hIL-4), corresponding to a specific activity of 2 x 105 units/mg.

Biological activity: Determined by its ability to inhibit the IL-4-dependent proliferation of human TF-1 cells. The expected ED50 is 5.0 ng/ml (in the presence of 0.5 ng/ml of hIL-4), corresponding to a specific activity of 2 x 105 units/mg.

Results: N/A

Binding Capacity: N/A

Unit Definition: N/A

Molecular Weight: ~24 kDa

Concentration: N/A

Appearance: Lyophilized powder

Physical form description: Sterile filtered through a 0.2 micron filter. Lyophilized from 1x PBS pH 7.0.

Reconstitution Instructions: Centrifuge the vial prior to opening. Reconstitute in water to a concentration of 0.1-1.0 mg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 week. For extended storage, it is recommended to further dilute in a buffer containing a carrier protein (example 0.1% BSA) and store in working aliquots at -20°C to - 80°C

Amino acid sequence: GNMKVLQEPT CVSDYMSIST CEWKMNGPTN CSTELRLLYQ LVFLLSEAHT CIPENNGGAG CVCHLLMDDV VSADNYTLDL WAGQQLLWKG SFKPSEHVKP RAPGNLTVHT NVSDTLLLTW SNPYPPDNYL YNHLTYAVNI WSENDPADFR IYNVTYLEPS LRIAASTLKS GISYRARVRA WAQCYNTTWS EWSPSTKWHN SYREPFEQH